Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00442533
Status:
COMPLETED
Last Update Posted:
2023-04-03
First Post:
2007-03-01
Brief Title:
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Sponsor:
Radio Isotope Therapy of America
Organization:
Radio Isotope Therapy of America
Study Overview
Official Title:
High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms
Status:
COMPLETED
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix is an effective treatment for Neuroendocrine Tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None